Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1

Physiology and Behavior

Volumn 154, Issue , 2016, Pages 135-144

  Sriram, Chandra Shaker ^a   Jangra, Ashok ^a   Gurjar, Satendra Singh ^a   Mohan, Pritam ^c   Bezbaruah, Babul Kumar ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b GAUHATI MEDICAL COLLEGE   (India)

^c ASSAM AGRICULTURAL UNIVERSITY   (India)

Author keywords

Anxiety; Depressive like behavior; Edaravone; Lipopolysaccharide; Poly(ADP ribose) polymerase 1

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATALASE; CORTICOSTERONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLUTATHIONE; INTERLEUKIN 1BETA; MALONALDEHYDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRITE; NORPHENAZONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, MOUSE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR CHANGE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE RELEASE; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FORCED SWIM TEST; HIPPOCAMPUS; LIGHT-DARK TEST; LIPID PEROXIDATION; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANXIETY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; IMMOBILIZATION; MAZE TEST; MENTAL DISORDERS; METABOLISM; PSYCHOLOGY; SWIMMING; VISUAL ADAPTATION;

ADAPTATION, OCULAR; ANIMALS; ANTIPYRINE; ANXIETY; CATALASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS; EXPLORATORY BEHAVIOR; FREE RADICAL SCAVENGERS; GLUTATHIONE; HINDLIMB SUSPENSION; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MENTAL DISORDERS; MICE; POLY(ADP-RIBOSE) POLYMERASES; SUPEROXIDE DISMUTASE; SWIMMING;

EID: 84948656368     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.10.029     Document Type: Article

References (80)

1. Agelaki S., Tsatsanis C., Gravanis A., Margioris A.N. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect. Immun. 2002, 70:6068-6074.
2. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 2012, 64:238-258.
3. Bassi G.S., Kanashiro A., Santin F.M., de Souza G.E.P., Nobre M.J., Coimbra N.C. Lipopolysaccharide-induced sickness behaviour evaluated in different models of anxiety and innate fear in rats. Basic Clin. Pharmacol. Toxicol. 2012, 110:359-369.
4. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., Allen N.B., Stuart A.L., Hayley A.C., Byrne M.L. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med. 2013, 11:200.
5. Beutler E., Duron O., Kelly B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61:882-888.
6. Biesmans S., Meert T.F., Bouwknecht J.A., Acton P.D., Davoodi N., De Haes P., Kuijlaars J., Langlois X., Matthews L.J.R., Ver Donck L. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediat. Inflamm. 2013, 2013.
7. Blanchard D.C., Griebel G., Blanchard R.J. Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci. Biobehav. Rev. 2001, 25:205-218.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
9. Buccafusco J.J. Methods of Behavior Analysis in Neuroscience 2009, CRC press, Augusta. 2nd ed.
10. Cadenas S., Cadenas A.M. Fighting the stranger-antioxidant protection against endotoxin toxicity. Toxicology 2002, 180:45-63.
11. Cubała W.J., Landowski J. Serotoninergic system and limbic-hypothalamic-pituitary-adrenal axis (LHPA axis) in depression. Psychiatr. Pol. 2005, 40:415-430.
12. Custódio C.S., Mello B.S.F., Cordeiro R.C., de Araújo F.Y.R., Chaves J.H., Vasconcelos S.M.M., Júnior H.V.N., de Sousa F.C.F., Vale M.L., Carvalho A.F. Time course of the effects of lipopolysaccharide on prepulse inhibition and brain nitrite content in mice. Eur. J. Pharmacol. 2013, 713:31-38.
13. Czapski G.A., Adamczyk A., Strosznajder R.P., Strosznajder J.B. Expression and activity of PARP family members in the hippocampus during systemic inflammation: their role in the regulation of prooxidative genes. Neurochem. Int. 2013, 62:664-673.
14. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
15. de Paiva V.N., Lima S.N.P., Fernandes M.M., Soncini R., Andrade C.A.F., Giusti-Paiva A. Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice. Behav. Brain Res. 2010, 215:146-151.
16. Dhir A., Kulkarni S.K. Nitric oxide and major depression. Nitric Oxide 2011, 24:125-131.
17. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., LanctÃ't K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
18. Duman R.S., Li N., Liu R.-J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
19. Espejo E.F. Effects of weekly or daily exposure to the elevated plus-maze in male mice. Behav. Brain Res. 1997, 87:233-238.
20. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin. Neurosci. 2008, 10:291.
21. Goswami D.B., Jernigan C.S., Chandran A., Iyo A.H., May W.L., Austin M.C., Stockmeier C.A., Karolewicz B. Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 43:126-133.
22. Hassa P.O., Hottiger M.O. The functional role of poly(ADP-ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol. Life Sci. CMLS 2002, 59:1534-1553.
23. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:2094-2095.
24. Henry C.J., Huang Y., Wynne A.M., Godbout J.P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines. Brain Behav. Immun. 2009, 23:309-317.
25. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy. J. Affect. Disord. 2001, 62:77-91.
26. Jangra A., Datusalia A.K., Khandwe S., Sharma S.S. Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: implication of oxidative stress-PARP pathway. Pharmacol. Biochem. Behav. 2013, 114:43-51.
27. Jangra A., Datusalia A.K., Sharma S.S. Reversal of neurobehavioral and neurochemical alterations in STZ-induced diabetic rats by FeTMPyP, a peroxynitrite decomposition catalyst and 1, 5-isoquinolinediol a poly (ADP-ribose) polymerase inhibitor. Neurol. Res. 2014, 36:619-626.
28. Jangra A., Lukhi M.M., Sulakhiya K., Baruah C.C., Lahkar M. Protective effect of mangiferin against lipopolysaccharide-induced depressive and anxiety-like behaviour in mice. Eur. J. Pharmacol. 2014, 740:337-345.
29. Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Mol. Brain Res. 2005, 136:29-37.
30. Khassaf M., McArdle A., Esanu C., Vasilaki A., McArdle F., Griffiths R.D., Brodie D.A., Jackson M.J. Effect of vitamin C supplements on antioxidant defence and stress proteins in human lymphocytes and skeletal muscle. J. Physiol. 2003, 549:645-652.
31. Kikuchi K., Takeshige N., Miura N., Morimoto Y., Ito T., Tancharoen S., Miyata K., Kikuchi C., Iida N., Uchikado H. Beyond free radical scavenging: beneficial effects of edaravone (radicut) in various diseases (review). Exp. Ther. Med. 2011, 3:3-8.
32. Kimpton J. The brain derived neurotrophic factor and influences of stress in depression. Psychiatr. Danub. 2012, 24:S169-S171.
33. Komada M., Takao K., Miyakawa T. Elevated plus maze for mice. J. Vis. Exp. 2008, 22.
34. Kono H., Asakawa M., Fujii H., Maki A., Amemiya H., Yamamoto M., et al. Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin. J. Pharmacol. Exp. Ther. 2003, 307(1):74-82.
35. Koo J.W., Duman R.S. Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci. Lett. 2009, 456:39-43.
36. Lacosta S., Merali Z., Anisman H. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Res. 1999, 818:291-303.
37. Lee S.-Y., Lee S.-J., Han C., Patkar A.A., Masand P.S., Pae C.-U. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46:224-235.
38. Li X., Frye M.A., Shelton R.C. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 2012, 37:77-101.
39. Licinio J., Wong M.L. Advances in depression research: 2011. Mol. Psychiatry 2011, 16:686-687.
40. Liu L., Song Y., Zhao M., Yi Z., Zeng Q. Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis. Int. Urol. Nephrol. 2015.
41. Lotrich F.E. Inflammatory cytokine-associated depression. Brain Res. 2014.
42. Lu S., Peng H., Wang L., Vasish S., Zhang Y., Gao W., Wu W., Liao M., Wang M., Tang H. Elevated specific peripheral cytokines found in major depressive disorder patients with childhood trauma exposure: a cytokine antibody array analysis. Compr. Psychiatry 2013, 54:953-961.
43. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:676-692.
44. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J. Affect. Disord. 2010, 125:287-294.
45. Messay B., Lim A., Marsland A.L. Current understanding of the bi-directional relationship of major depression with inflammation. Biol. Mood Anxiety Disord. 2012, 2:4.
46. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
47. Miller S.I., Ernst R.K., Bader M.W. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 2005, 3:36-46.
48. Nisselbaum J.S., Green S. A simple ultramicro method for determination of pyridine nucleotides in tissues. Anal. Biochem. 1969, 27:212-217.
49. Ohgi Y., Futamura T., Kikuchi T., Hashimoto K. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 2013, 103:853-859.
50. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
51. Patki G., Solanki N., Atrooz F., Allam F., Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res. 2013, 1539:73-86.
52. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
53. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 463(1-3):3-33.
54. Qi X., Okuma Y., Hosoi T., Nomura Y. Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction. J. Pharmacol. Exp. Ther. 2004, 311:388-393.
55. Qin J., Zhang R.-X., Li J.-L., Wang J.-X., Hou J., Yang X., Zhu W.-L., Shi J., Lu L. CRGD mediated liposomes enhanced antidepressant-like effects of edaravone in rats. Eur. J. Pharm. Sci. 2014, 58:63-71.
56. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
57. Risbrough V.B., Stein M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav. 2006, 50:550-561.
58. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 2012, 62:202-209.
59. Salim S., Chugh G., Asghar M. Inflammation in anxiety. Adv. Protein Chem. Struct. Biol. 2012, 88:1-25.
60. Schüle C., Baghai T.C., Eser D., Rupprecht R. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev. Neurother. 2009.
61. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res. 1996, 64:161-167.
62. Song C., Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:760-768.
63. Srinivasan K., Sharma S.S. Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. Basic Clin. Pharmacol. Toxicol. 2011, 110:133-140.
64. Sriram C.S., Jangra A., Gurjar S.S., Hussain M.I., Borah P., Lahkar M., Mohan P., Bezbaruah B.K. Poly(ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice. Pharmacol. Biochem. Behav. 2015, 133:83-91.
65. Sriram C.S., Jangra A., Kasala E.R., Bodduluru L.N., Bezbaruah B.K. Targeting poly(ADP-ribose) polymerase1 in neurological diseases: a promising trove for new pharmacological interventions to enter clinical translation. Neurochem. Int. 2014, 76:70-81.
66. Sriram C.S., Jangra A., Madhana R.M., Gurjar S.S., Mohan P., Bezbaruah B.K. Multiple facets of poly(ADP-ribose) polymerase-1 in neurological diseases. Neural Regen. Res. 2015, 10:49-51.
67. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
68. Sulakhiya K., Kumar P., Gurjar S.S., Barua C.C., Hazarika N.K. Beneficial effect of honokiol on lipopolysaccharide induced anxiety-like behavior and liver damage in mice. Pharmacol. Biochem. Behav. 2015, 132:79-87.
69. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. J. Affect. Disord. 2001, 63:221-224.
70. Tajima S., Soda M., Bando M., Enomoto M., Yamasawa H., Ohno S., Takada T., et al. Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice. Respirology 2008, 13(5):646-653.
71. Tomaz V.S., Cordeiro R.C., Costa A.M.N., De Lucena D.F., Junior H.V.N., De Sousa F.C.F., Vasconcelos S.M.M., Vale M.L., Quevedo J., Macêdo D. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience 2014, 268:236-246.
72. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. J. Am. Med. Assoc. 2013, 310:591-608. US Burden Of Disease Collaborators.
73. Vogelzangs N., Beekman A.T.F., De Jonge P., Penninx B. Anxiety disorders and inflammation in a large adult cohort. Transl. Psychiatry 2013, 3:e249.
74. Wang Z., Zhang Q., Yuan L., Wang S., Liu L., Yang X., Li G., Liu D. The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration. Behav. Brain Res. 2014, 274:282-290.
75. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry 2002.
76. Xu Y., Wang C., Klabnik J.J., O'Donnell J.M. Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment. Curr. Neuropharmacol. 2014, 12:108.
77. Yuan Y., Zha H., Rangarajan P., Ling E., Wu C. Anti-inflammatory effects of edaravone and scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. BMC Neurosci. 2014, 15:125.
78. Zeugmann S., Buehrsch N., Bajbouj M., Heuser I., Anghelescu I., Quante A. Childhood maltreatment and adult proinflammatory status in patients with major depression. Psychiatr. Danub. 2013, 25:227-235.
79. Zong L., Yu Q.H., Du Y.X., Deng X.M. Edaravone protects endotoxin-induced liver injury by inhibiting apoptosis and reducing proinflammatory cytokines. Braz. J. Med. Biol. Res. 2014, 47(3):231-236.
80. Zunszain P.A., Anacker C., Cattaneo A., Carvalho L.A., Pariante C.M. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:722-729.